Get the Stockscreener App
6.00
30.15%
1.39
After Hours:
6.65
0.65
+10.83%
Jupiter Neurosciences Inc stock is traded at $6.00, with a volume of 165.18K.
It is up +30.15% in the last 24 hours and up +3,202% over the past month.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
See More
Previous Close:
$4.61
Open:
$4.62
24h Volume:
165.18K
Relative Volume:
0.01
Market Cap:
$4.62M
Revenue:
$40,400
Net Income/Loss:
$-9.18M
P/E Ratio:
-22.35
EPS:
-0.2684
Net Cash Flow:
$-5.78M
1W Performance:
+7,889%
1M Performance:
+3,202%
6M Performance:
+938.24%
1Y Performance:
+383.87%
1-Day Range:
$4.62
$6.10
1-Week Range:
$4.56
$6.10
52-Week Range:
$0.071
$6.10
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Name
Jupiter Neurosciences Inc
Sector
Industry
Phone
(561) 406-6154
Address
1001 NORTH US HWY 1, JUPITER
Compare JUNS vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
6.00 | 3.55M | 40,400 | -9.18M | -5.78M | -0.2684 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Jupiter Neurosciences Inc Stock (JUNS) Latest News
Jupiter Neurosciences Stock Short Interest Falls to 34.91% - Quiver Quantitative
A Tiny Psychedelic Stock Just Exploded Over 50% – Retail Traders Think $1 Is Next - Stocktwits
Stock Splits Calendar for: - Yahoo! Finance Canada
Calendrier des fractionnements d'actions pour: - Yahoo Finance France
Form 8K Jupiter Neurosciences Inc For: 6 August By Investing.com - Investing.com Nigeria
Jupiter Neurosciences Announces 1-for-75 Reverse Stock Split to Regain Nasdaq Compliance - Minichart
Jupiter Neurosciences Enacts 1-for-75 Reverse Stock Split - TipRanks
Jupiter Neurosciences Inc (JUNS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jupiter Neurosciences executes 1-for-75 reverse stock split By Investing.com - Investing.com UK
Jupiter Neurosciences grants 472,222 director options | JUNS Insider Trading - Stock Titan
Jupiter Neurosciences executes 1-for-75 reverse stock split - Investing.com
Jupiter Neurosciences, Inc. Announces 1-for-75 Reverse Stock Split Effective August 6, 2026 - Quiver Quantitative
Jupiter Neurosciences, Inc. Announces Reverse Stock Split - GlobeNewswire
Jupiter Neurosciences announces 1-for-75 revers... - Pluang
Kaskela Law Firm Announces Stockholder Investigation of Jupiter N - The National Law Review
Jupiter Neurosciences expands into psychedelics with $100m deal - Longevity.Technology
Jupiter Neurosciences (Nasdaq: JUNS) sells 11.47M shares under SEPA - Stock Titan
Jupiter Neurosciences Inc (JUNS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jupiter Neurosciences Stockholders Approve Key 2026 Actions - TipRanks
Jupiter Neurosciences, Inc. Files Form 8-K: Key Details on Nasdaq Listing, Address, and Corporate Status - Minichart
Jupiter Neurosciences (NASDAQ: JUNS) details Yorkville SEPA terms - Stock Titan
Jupiter Neurosciences Inc (JUNS) Cash Flow - TradingKey
Jupiter Neurosciences Inc (JUNS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jupiter Neurosciences Inc (JUNS) Balance Sheet - TradingKey
Jupiter Neurosciences, Inc. Revenue Breakdown – NASDAQ:JUNS - TradingView
What is Driving Jupiter Neurosciences' Recent Stock Volatility - Kavout | AI
Jupiter Neurosciences Inc (JUNS) Institutional Confidence - TradingKey
Jupiter Neurosciences Expands CNS Pipeline with $100M ALA-002 Licensing DealEPS Surprise History - dars.gov.et
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences - TipRanks
Jupiter Neurosciences licenses MDMA drug in deal worth up to $100M - Dealroom
JUNS|Jupiter Neurosciences Inc|Price:0.148|Chg%:-0.005 - TradingKey
Jupiter Neurosciences director Andrew Jon Cutler files initial beneficial ownership statement - Bitget
Jupiter Neurosciences Secures Exclusive US Rights for ALA-002 - sekbernews.id
Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva - Yahoo Finance
CNS drug specialist Jupiter Neuro signs MDMA deal with PharmAla Biotech - Mugglehead Investment Magazine
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 - EIN Presswire
Jupiter Neurosciences acquires US rights to ALA-002 in deal worth up to $100M - MSN
Jupiter Neurosciences licenses MDMA drug ALA-002 - BioXconomy
PharmAla Biotech Licenses Lead Candidate ALA-002 to Jupiter Neuroscience in the US - Moomoo
Jupiter Neurosciences signs ALA-002 license agreement worth up to $100 million (NASDAQ:JUNS) - MSN
Jupiter Neurosciences expands CNS pipeline with $100 million PharmAla MDMA deal - The Pharma Letter
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 - Investing News Network
Jupiter Neurosciences Licenses ALA-002 for U.S. Development - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Jupiter Neurosciences (Nasdaq: JUNS) to license ALA-002 in US - Stock Titan
Jupiter Neurosciences Stock (JUNS) Jumps on a New License Deal - TipRanks
Jupiter Neurosciences (NASDAQ:JUNS) surge cools as $100 million MDMA agreement strains funding resources - TechStock²
Tuesday's session: most active stocks - ChartMill
Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS) - Yahoo Finance
Jupiter enters psychedelics space with $100M deal for MDMA drug - Fierce Biotech
PharmAla Biotech Grants Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 in $100M Licensing Deal - Kalkine Media
Jupiter Neurosciences Inc Stock (JUNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):